ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1840

Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial

Sharzad Emamikia1, Cidem Gentline1, Elizabeth V. Arkema2, Laurent Arnaud3, Katerina Chatzidionysiou1,4 and Ronald F van Vollenhoven5,6, 1Department of Medicine, (ClinTRID), Karolinska Institute, Stockholm, Sweden, 2Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 3Department of Rheumatology, Université de Strasbourg, Strasbourg, France, 4On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, 5Department of Medicine, (ClinTRID), Karolinska Institute, Solna, Sweden, 6AMC, F4-214, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: SLE and remission

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Remission in SLE is a desirable target, however there is no gold standard for the definition of remission. An international task force agreed on various definitions of remission in SLE (DORIS) [1]. Our aim was to apply these definitions on a clinical trial.

Methods: This is a post-hoc analysis of a prospective randomized controlled trial (RCT) in SLE, the BLISS-76 clinical trial [2]. We have applied two DORIS definitions (Table 1) at three time points, week (wk) 24, 52 and 76. The patient could be in remission on or off treatment. Remission on treatment allowed maintenance anti-malarials, low dose glucocorticoids (GCs) (prednisone ≤ 5 mg/day or equivalent), maintenance immunosuppressives and maintenance biologics. Remission off treatment allowed maintenance anti-malarials only. Additionally, we applied each definition where the remission on treatment allowed a GC dose  ≤ 10 mg/day (not a part of the original DORIS-definitions).

Results: There were 819 patients enrolled in BLISS-76. The baseline characteristics are shown in Table 2.  The proportions of patients that fulfilled remission according to the above definitions are shown in Table 3. The highest point prevalence (9.5%) was when definition 1a on treatment was applied at wk 76. As expected, even more patients fulfilled definition 1a when a GC dose  ≤ 10 mg/day was allowed at wk 76 (13.8%).  More patients fulfilled the remission criteria when clinical SLEDAI was used compared to when BILAG was used. When serology (anti-DNA antibodies and complement)  was taken into consideration (definitions 1b and 3b), less patients fulfilled remission. Very low numbers of patients (≤1%) fulfilled remission off treatment.

Conclusion: Overall, few patients fulfilled remission according to these definitions. More patients fulfilled the definitions when serology was excluded and when a higher dose of GCs was allowed.

References

1.                          van Vollenhoven R, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the rheumatic diseases. 2016.

2.                          Furie R, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30.


Disclosure: S. Emamikia, None; C. Gentline, None; E. V. Arkema, None; L. Arnaud, Amgen, Astra-Zeneca, GSK, Lilly, Pfizer, Roche, 5; K. Chatzidionysiou, Lilly, AbbVie, Pfizer, Roche, Sandoz, 5; R. F. van Vollenhoven, AbbVie, Amgen, Biotest, BMS, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, 2,AbbVie, Amgen, Biotest, BMS, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, 5,AbbVie, Amgen, Biotest, BMS, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, 9.

To cite this abstract in AMA style:

Emamikia S, Gentline C, Arkema EV, Arnaud L, Chatzidionysiou K, van Vollenhoven RF. Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparison-of-different-definitions-of-remission-in-systemic-lupus-erythematosus-sle-a-study-based-on-the-bliss-76-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-different-definitions-of-remission-in-systemic-lupus-erythematosus-sle-a-study-based-on-the-bliss-76-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology